Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

Pharma Two B (Israel), a pre-clinical stage pharmaceutical company focused on developing Fixed-Dose-combinations of approved drugs for Parkinson’s disease and Cancer, closed a $8 million Series B financing. Participants include JK&B Capital and Crossroad. ___________ Collective IP the Most Comprehensive and Accurate View of Global Innovation and Organization of the International Technology Transfer Office Ecosystem

Aragon Pharmaceuticals (San Diego, CA) a clinical-stage small molecule company focused on the treatment of hormone-resistant cancers, with an intital focuse on prostate and breast cancer, closed a $42M Series C financing. Participants include Aisling Capital, OrbiMed, Column Group and Topspin Partners. Note: Closing out 1Q deals. Thanx for your patience as we play catch-up.

ViewRay (Oakwood Village, OH) a clinical-stage medical device company focused on MRI-guided radiation therapy system for the treatment of various cancers, closed a $26.3M Series C financing, bringing the total round to $45M. Participants include Aisling Capital, Fidelity Biosciences, Kearny Venture Partners, OrbiMed and Siemens Venture Capital.

ImaginAb (Inglewood, CA) a clinical-stage biopharmaceutical company focused on re-engineered therapeutic antibody fragments against biologic targets for diagnostic imaging with Positron Emission Tomography scans for management of cancer and autoimmune disease, closed a $12.5M Series B financing. Participants include Novartis Venture Funds, Merieux Developpement, Nextech Invest, Cycad Group and Momentum Biosciences.

Mevion Medical Systems (Littleton, MA) a commercial-stage medical device company focused on proton beam radiotherapy device for cancer, closed a $45M Series G financing. Participants include ProQuest Investment, Caxton Heath Life Sciences, Venrock and CHL Medical Partners.

ImmuneXcite (Watertown, MA) a development-stage biopharmaceutical company focused on a therapeutic platform for the development of monoclonal antibodies and vaccines for cancer and infectious diseases, closed a $2.4M Series A financing. Participants include Boston Harbor Angels.

Heat Biologics (Chapel Hill, NC) a clinical-stage biopharmaceutical company focused on vaccines and antibodies for non-small cell lung cancer and stimulation of regulatory T cells, closed a $2.8M Series A financing. Participants include Brightline Ventures.

CrystalGenomics (Korea) a clinical-stage biopharmaceutical company focused on chemoproteomics based drug discovery company working on an NSAID, antibiotics for MRSA and HIF inhibitors for hypoxia, therapeutics for cancer, closed a third tranche of $2.6M Series A financing bringing the total round to $20M. Participants include Korea Seoul Life Sciences Fund, Hanwha Venture Capital and Oxford […]

MedGenesis Therapeutix (Canada) a clinical-stage biopharmaceutical company focused on glial cell-derived neurotrophic factor protein for CNS diseases such as Parkinson’s disease, epilepsy and sensorineural hearing loss, closed a $5M Series C financing. Participants were not disclosed.

AirXpanders (Palo Alto, CA) a clinical-stage biotechnology company focused on implantable breast tissue expanders for breast cancer masectomy patients, closed a $10M Series D financing. Participants include Vivo Ventures, GBS Venture Partners, Prolog Ventures, Heron Capital and Western Technology Innovation.

ImmuneXcite (Watertown, MA) a development-stage biopharmaceutical company focused on a therapeutic platform for the development of monoclonal antibodies and vaccines for cancer and infectious diseases, closed a $2.4M Series A financing. Participants include Boston Harbor Angels.

BerGenBio (Norway) a preclinical-stage biopharma company focused on receptor tyrosine kinase inhibition for the treatment of cancer, closed a $8.8M Series A financing. Participants include Sarsia Seed and Investinor.

Telormedix (Switzerland) a clinical-stage biopharmaceutical company focused on Toll-like receptor agonists for bladder cancer and autoimmune disease, closed a $8.3M Series B financing. Participants include Aravis Venture and Proquest Investments.

« Previous Page« Previous Entries  Next Entries »Next Page »

to top of page...